Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Pfizer Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (513)
ARTG (459)
Australian public assessment report (AusPar) (68)
Prescription medicine registration (44)
Section 14, TGO91 consent (21)
Prescription medicine decision summary (19)
Designation or determination (9)
Cancellation or suspension (7)

Date

2026 (1)
2025 (38)
2024 (86)
2023 (73)
2022 (59)
2021 (124)
2020 (107)
2019 (98)
2018 (95)
2017 (73)
2016 (12)
2015 (22)
2014 (19)
2013 (9)
2012 (8)
2011 (14)
2010 (27)
2009 (13)
2008 (5)
2007 (11)
2006 (8)
2005 (4)
2004 (8)
2003 (3)
2002 (10)
2001 (6)
2000 (20)
1999 (9)
1998 (12)
1997 (16)
1996 (8)
1995 (3)
1994 (31)
1993 (17)
1992 (5)
1991 (86)

Search

Sponsor content

1140 result(s) found, displaying 421 to 430

DBL DOXORUBICIN HYDROCHLORIDE 50mg/25ml injection vial Cancelled under Section 30(1)(c) of the Act

17 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
DBL Remifentanil powder for injection (remifentanil hydrochloride) 2 mg/vial Cancelled under Section 30(1)(c) of the Act

16 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
DBL Remifentanil powder for injection (remifentanil hydrochloride) 5 mg/vial Cancelled under Section 30(1)(c) of the Act

16 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
DBL Remifentanil powder for injection (remifentanil hydrochloride) 1 mg/vial Cancelled under Section 30(1)(c) of the Act

16 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
CISATRACURIUM PFIZER cisatracurium (as besilate) 5 mg/2.5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
CISATRACURIUM PFIZER cisatracurium (as besilate) 10 mg/5 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
CISATRACURIUM PFIZER cisatracurium (as besilate) 20 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

14 December 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 400 mg/200 mL bag Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
ROPIVACAINE PFIZER ropivacaine hydrochloride solution for injection 200 mg/100 mL bag Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd
HOSPIRA ROPIVACAINE HYDROCHLORIDE INJECTION ropivacaine hydrochloride (as monohydrate) 75 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

26 November 2020

Cancellation by sponsor

Requested by Pfizer Australia Pty Ltd

Pages

First page
Previous page
…
Page 39
Page 40
Page 41
Page 42
Current page 43
Page 44
Page 45
Page 46
Page 47
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.